Sign inThe Canadian Agency for Drugs and Technologies in Health (CADTH) is an independent, not-for-profit agency funded by Canadian federal, provincial, and territorial governments to provide credible, impartial advice and evidence-based information about the effectiveness of drugs and other health technologies to Canadian health care decision makers. Here is an overview of CADTH's recent Vancouver symposium.
Monday, April 4, 2011 - Concurrent Sessions |
|||||
|
1100 – 1230 |
Concurrent Session A1: Evidence, Ethics, and Quality: Issues in Health Technology Assessment Methodology |
Ms. Katherine Duthie Dr. Maurice McGregor Dr. Aaron Tejani Dr. Ken Bassett Mr. Ciprian Jauca |
|||
|
Concurrent Session A2: Evidence-Based Policy-Making: What Works? |
Dr. John Embil |
||||
|
Concurrent Session A3: HTA in Hospitals: Reflections and Perceptions |
Ms. Carmen Thompson Dr. Sue Ross |
||||
|
Concurrent Session A4: Behavioural Change |
Dr. Terryn Naumann |
||||
|
Concurrent Session A5: Health Economics |
Dr. Nick Bansback |
||||
|
Concurrent Session A6: Moving from Evidence to Practice |
Dr. Sarah Jennings Mr. Alan Cassels Dr. Bing Guo |
||||
|
Concurrent Session A7: Health Technology Assessment and Oncology |
Dr. Wendong Chen Ms. Zahra Musa Mr. Mike Paulden Dr. Paulos Teckle |
||||
|
1330 – 1500 |
Concurrent Session B1: PANEL DISCUSSION: Greater Than the Sum of Its Parts: Melding and Adapting Seven Guidelines |
Ms. Christa Harstall Dr. Carmen Moga Dr. Ann Scott Dr. Werner Becker |
|||
|
|
Concurrent Session B2: PANEL DISCUSSION: Health Technology Assessment for Health System Sustainability: Opportunities and Challenges |
Dr. Arminee Kazanjian |
|||
|
|
Concurrent Session B3: PANEL DISCUSSION: Health Technology Assessment and Comparative Effectiveness Topic Development and Priority Setting: Overview of Canadian and International Processes |
Ms. Sandy Pagotto Dr. Reiner Banken |
|||
|
|
Concurrent Session B4: PANEL DISCUSSION: Improving Health Outcomes and Health Care System Sustainability, and Encouraging Innovation by Collaborating with Industry |
Ms. Leah Clark |
|||
|
|
Concurrent Session B6: PANEL DISCUSSION: How Can Decision-Makers Consider Other Factors in Decision-Making: Multi-Criteria to Maximize Opportunities to Bring Evidence into Practice? |
Dr. Janet Martin Dr. Tammy Clifford |
|||
|
|
Concurrent Session B7: PANEL DISCUSSION: Openness in Health Technology Assessments |
Ms. Lynn Buchanan Dr. Andreas Laupacis Dr. Martin Zagari |
|||
|
1530 – 1700 |
Concurrent Session C1: Decision-Maker Support |
Mr. Pavel Roshanov |
|||
|
|
Concurrent Session C2: Pharmaceutical Issues |
Dr. Barbara Mintzes Mr. Shawn Bugden |
|||
|
|
Concurrent Session C3: Emerging Technologies/ |
||||
|
|
Concurrent Session C4: Priority Setting and Resource Allocation |
||||
|
|
Concurrent Session C5: Evidence to Practice |
Dr. Alison Hoens |
|||
|
|
Concurrent Session C6: |
Dr. Robin Turpin Dr. Mehdi Najafzadeh |
|||
|
|
Concurrent Session C7: Evidence-Based Cost Savings |
Dr. Larry Lynd Dr. Jeffrey Hoch |
|||
Tuesday, April 5, 2011 |
|||||
|
0830 – 0945 |
Plenary Session: Maximizing Our Investment in Clinical Practice Guidelines |
Dr. Stirling Bryan Dr. Norman Campbell Dr. Scott Klarenbach Dr. Valerie Palda Dr. Martin Reed |
|||
|
1015 – 1145 |
Concurrent Session D1: PANEL DISCUSSION: Value-Based Drug Reimbursement: Do We Want It? Do We Already Have It? |
Dr. Jeffrey Hoch |
|||
|
Concurrent Session D2: PANEL DISCUSSION: The Drug Safety and Effectiveness Network (DSEN): Evidence for Informed Decisions |
Dr. Robert Peterson Mr. Bob Nakagawa Dr. Diane Forbes Dr. Christian Brochu Dr. Chris Turner Dr. Colin Dormuth |
||||
|
Concurrent Session D3: PANEL DISCUSSION: Using CADTH Recommendations for Self-Monitoring of Blood Glucose in Nova Scotia: Go Fast Alone or Go Far Together |
Dr. Michael Allen Ms. Peggy Dunbar Ms. Isobel Fleming Ms. Corinne Tobin Ms. Pam McLean-Veysey |
||||
|
Concurrent Session D4: PANEL DISCUSSION: Alberta Health Services and Advancing the Uptake of Health Technology Assessment and Innovation: An Update on Alberta’s Experience |
Ms. Rosmin Esmail Dr. Lea Austen Mr. Jitendra Prasad |
||||
|
Concurrent Session D5: PANEL DISCUSSION: CSI: A Café Scientifique Investigation †Using Café to Demystify Recommendations, Engage Audiences, and Address Barriers |
Dr. Adil Virani |
||||
|
1315 – 1445 |
Concurrent Session E1: PANEL DISCUSSION: Building Bridges: Regulatory Science and Reimbursement Decision-Making |
Dr. Stuart MacLeod |
|||
|
|
Concurrent Session E2: PANEL DISCUSSION: Guideline Development: Overcoming Challenges of Limited Evidence and Implementation at a National Level |
Mr. Clarence Weppler Ms. Emma Irvin Dr. Michael Allen Dr. Norman Buckley |
|||
|
|
Concurrent Session E3: PANEL DISCUSSION: Eyes Wide Open: Using Evidence to Rethink the Treatment Model for Type 2 Diabetes in Canada |
Mr. Chris Cameron |
|||
|
|
Concurrent Session E4: PANEL DISCUSSION: Surrogate Markers in Health Technology Assessment: To Use or Not To Use Is the Question |
Dr. Charles Piwko Dr. Jeffery Hoch |
|||
|
|
Concurrent Session E5: Public Engagement |
Mr. Harlon Davey |
|||
|
|
Concurrent Session E6: Policy Issues Across Canada |
Dr. Aaron Tejani Mr. Sean Hardiman Dr. Joel Lexchin |
|||
|
1500 – 1615 |
Closing Plenary: Maximizing Our Investment in Health Technologies |
Dr. Sarah Garner Dr. Clifflord Goodman Dr. Chris Henshall Ms. Diane McArthur Dr. Brian O’Rourke |
|||
Some presentations have not been posted at the request of the authors.
Commenting on this Blog entry is closed.
